<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012072410385N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2013-02-04</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences, Vice Chancellor for research</primary_sponsor>
      <public_title>Comparison of controlled and spontaneous respiration on postoperative nausea and vomiting and laryngospasm in children</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of the incidence of  post operative nausea and vomiting and laryngospasm in controlled ventilation or spontaneous respiration in children underwent elective inguinal or femoral hernia surgery with general anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2010-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>200</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/10892</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Elective inguinal or femoral hernia.</hc_freetext>
      <i_freetext>Intervention 1: In spontaneous respiration group, after primary monitoring with ECG, SpO2 and NIBP and after induction of anesthesia with intra-venous fentanyl 1microg/Kg (Rotex Medica Manufactory), thiopentone 4mg/Kg (Rotex Medica Manufactory) and after increasing the dose of inhalation halothane (from 1 to 4%) (Nicholas Piramal India  Manufactory) and when the optimal depth of anesthesia will be established, the patients will be intubated with an uncuffed  tracheal tube, and the patients will be allowed to breath spontaneously. The anesthetic gas (Halothane 2% in equal dose of O2 and N2O) will be delivered to patients by a mapelson system. Neostigmine-atropine (Rasht Pharmaceutical  Manufactory) will not be injected in patients in spontaneous respiration group at the end of surgery. The patients will be extubated in a light plan of anesthesia (movement of head and hands). Intervention 2: In control ventilation group,  after primary monitoring with ECG, SpO2 and NIBP  and after induction of anesthesia with intra-venous  fentanyl  1microg/Kg (Rotex Medica Manufactory), thiopentone 4mg/Kg (Rotex Medica Manufactory), intra-venous  atracurium(0.6 mg/kg) (Abooreyhan Manufactory) will be injected as muscle relaxant before intubation. After intubation with an uncuffed tracheal tube, the anesthetic gas (Halothane 2% in equal dose of O2 and N2O) will be delivered to patients by a circle system of anesthetic machine. The tidal volume will be set as 8-10 ml/kg and respiratory rate between 14-16 rate/minute. At the end of surgery, the muscle relaxant will be antagonized with neostigmine  50 microgram per kilogram-atropine 25 microgram per kilogram (Rasht Pharmaceutical Manufactory) in control ventilation group. The patients will be extubated in a light plan of anesthesia (movement of head and hands).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahriari Ali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Roozbeh Hospital, South Kargar Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 5560 9951</telephone>
        <email>Ashahriari@tums.ac.ir ;alibenmahdi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences,</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahriari Ali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Roozbeh Hospital. South Kargar Street.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 5560 9951</telephone>
        <email>Ashahriari@tums.ac.ir ;alibenmahdi@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences,</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: children admitted for elective inguinal or femoral hernia surgery. &#13;
Exclusion criteria: History of asthma;  Fever;  Morbid obesity; Cardiac disease;  Metabolic disease ;  Renal disease; Electrolyte imbalance;  SpO2  under %85</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>7 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K40.2, K40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bilateral inguinal hernia, without obstruction or gangrene, Unilateral or unspecified inguinal hernia, without obstruction or gangrene, Bilateral femoral hernia, without obstruction or gangrene, Unilateral or unspecified femoral hernia, without obstructio</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In spontaneous respiration group, after primary monitoring with ECG, SpO2 and NIBP and after induction of anesthesia with intra-venous fentanyl 1microg/Kg (Rotex Medica Manufactory), thiopentone 4mg/Kg (Rotex Medica Manufactory) and after increasing the dose of inhalation halothane (from 1 to 4%) (Nicholas Piramal India  Manufactory) and when the optimal depth of anesthesia will be established, the patients will be intubated with an uncuffed  tracheal tube, and the patients will be allowed to breath spontaneously. The anesthetic gas (Halothane 2% in equal dose of O2 and N2O) will be delivered to patients by a mapelson system. Neostigmine-atropine (Rasht Pharmaceutical  Manufactory) will not be injected in patients in spontaneous respiration group at the end of surgery. The patients will be extubated in a light plan of anesthesia (movement of head and hands).</i_keyword>
      <i_keyword>In control ventilation group,  after primary monitoring with ECG, SpO2 and NIBP  and after induction of anesthesia with intra-venous  fentanyl  1microg/Kg (Rotex Medica Manufactory), thiopentone 4mg/Kg (Rotex Medica Manufactory), intra-venous  atracurium(0.6 mg/kg) (Abooreyhan Manufactory) will be injected as muscle relaxant before intubation. After intubation with an uncuffed tracheal tube, the anesthetic gas (Halothane 2% in equal dose of O2 and N2O) will be delivered to patients by a circle system of anesthetic machine. The tidal volume will be set as 8-10 ml/kg and respiratory rate between 14-16 rate/minute. At the end of surgery, the muscle relaxant will be antagonized with neostigmine  50 microgram per kilogram-atropine 25 microgram per kilogram (Rasht Pharmaceutical Manufactory) in control ventilation group. The patients will be extubated in a light plan of anesthesia (movement of head and hands).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Nausea. Timepoint: Every 15 minutes to 6 hours after the end of the intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Vomiting. Timepoint: Every 15 minutes to 6 hours after the end of the intervention. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Laryngospasm. Timepoint: Every  minute to 30 minutes after the end of intervention. Method of measurement: Pulse oxymetry device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences, Vice Chancellor for research</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-12-30</approval_date>
        <contact_name>Ethics committee of Tehran University Of Medical Sciences</contact_name>
        <contact_address>Qods St, Keshavarz Blvd Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2009-01-29</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University Of Medical Sciences</contact_name>
        <contact_address>Yemen St. Shahid Chamran Highway. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
